Louisiana’s Novel ‘Subscription’ Model For Pricey Hepatitis C Drugs Gains Approval
Louisiana officials announced a deal Wednesday with Asegua Therapeutics, a subsidiary of Gilead Sciences, that would allow the state to provide hepatitis C treatment to its Medicaid and prison populations. They also secured the necessary clearance from the federal government Wednesday for a novel approach to paying for the drugs and expect the program to start July 15.
Leave a Reply
You must be logged in to post a comment.